Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations (Unaudited)

v3.25.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]        
Research and development $ 1,220,535 $ 1,062,672 $ 2,535,394 $ 2,332,892
General and administrative 1,367,616 1,697,787 2,464,881 2,971,245
Total operating expenses 2,588,151 2,760,459 5,000,275 5,304,137
Loss from operations (2,588,151) (2,760,459) (5,000,275) (5,304,137)
Other (income) expenses:        
Interest expense 59,696 31,838 119,393 31,838
Interest income (7,067) (75,522) (33,073) (130,720)
Grant income (177,703) (423,065)
Other (47) 594 236 (7,063)
Other income, net (125,121) (43,090) (336,509) (105,945)
Net loss $ (2,463,030) $ (2,717,369) $ (4,663,766) $ (5,198,192)
Weighted average common shares outstanding, basic 27,415,430 25,789,739 26,674,324 25,711,478
Weighted average common shares outstanding, diluted 27,415,430 25,789,739 26,674,324 25,711,478
Net loss per share, basic $ (0.09) $ (0.11) $ (0.17) $ (0.20)
Net loss per share, diluted $ (0.09) $ (0.11) $ (0.17) $ (0.20)